Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) will launch Liv18™ in the U.S. in Q2 2026, a 600 mg/day liver health supplement powered by patented BergacynFF®, supported by two randomized, double‑blind, placebo‑controlled trials showing 9–15% liver fat reduction versus placebo.

Products are manufactured in GMP, FDA‑registered U.S. facilities and target the $4.6B U.S. liver supplements market.

Positive

• Liver fat ↓9–15% vs placebo in two RCTs
• 600 mg/day clinical dose validated in human trials
• U.S. commercial launch scheduled for Q2 2026
• Manufactured in GMP, FDA‑registered U.S. facilities
• Targets $4.6B U.S. liver supplements market with 4.9% CAGR

Negative

• None.

News Market Reaction – COSM

+0.57%

2 alerts

+0.57% Session close to close

+8.4% Peak Tracked

$10.86M Market Cap

0.4x Rel. Volume

In the Apr 8 session, COSM gained 0.57%, reflecting a mild positive market reaction. Argus tracked a peak move of +8.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details the planned Q2 2026 U.S. launch of Liv18™, a liver health supplement power...

Analysis

This announcement details the planned Q2 2026 U.S. launch of Liv18™, a liver health supplement powered by patented BergacynFF® at a clinically studied 600 mg/day dose, supported by two randomized controlled trials showing 9–15% liver fat reductions vs placebo. It adds to Cosmos Health’s expansion into large, growing categories like the $4.6B U.S. liver health supplements market. Investors may watch execution across U.S. channels, ongoing product data, and how this complements prior growth and asset-focused disclosures.

Key Figures

U.S. NAFLD/MASLD prevalence: >30% of adults Liver health supplements market: $4.6B Market growth: 4.9% CAGR +5 more

8 metrics

U.S. NAFLD/MASLD prevalence >30% of adults Metabolic Dysfunction-Associated Steatotic Liver Disease prevalence in U.S. adults

Liver health supplements market $4.6B U.S. liver health supplements market size

Market growth 4.9% CAGR Projected U.S. liver health supplements market growth through 2035

Study 1 sample size 80 subjects NAFLD + Type 2 Diabetes, 16-week randomized trial

Study 2 sample size 102 subjects Non-diabetic, age 35–70, liver steatosis, 12-week trial

Liver fat reduction 9% vs placebo Overall reduction in Study 2 at 600 mg/day BergacynFF

Liver fat reduction >50 yrs 15% Subjects >50 years in Study 2 vs placebo

Liv18 dose 600 mg/day BergacynFF per day, matching dose used in published RCTs

Previous Crypto Reports

5 past events · Latest: Apr 01 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Product efficacy data	Positive	+0.6%	EN 12791 study confirmed C‑Scrub Wash 4% meets surgical hand disinfection standards.
Mar 19	Strategic & guidance	Positive	-0.4%	Record growth, high-margin U.S. expansion, and valuation-focused update with future guidance.
Mar 11	Crypto treasury move	Positive	+1.1%	Purchase of $600,000 Bitcoin, lifting digital assets to $3.1M for treasury diversification.
Feb 19	Asset value highlight	Positive	-5.9%	Highlighted $15M Athens real estate value exceeding market cap and explored monetization options.
Feb 18	Retail expansion	Positive	+9.5%	C‑Scrub listing at Superdrug, expanding UK and Ireland retail and pharmacy reach.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Same-tag news has produced mixed reactions, with several clearly positive operational and asset value updates still seeing negative or modest price responses.

Recent Company History

Over the past few months, Cosmos Health issued multiple "crypto"-tagged updates spanning operations, assets, and strategy. These include UK retail expansion for C‑Scrub (Superdrug listing) on Feb 18, 2026, highlighting over 830 stores, and a $15M real-estate value disclosure exceeding prior market cap on Feb 19. The company also expanded digital assets to $3.1M, outlined record growth and U.S. expansion with high-margin products, and reported positive EN 12791 surgical hand antisepsis data. Today’s U.S. Liv18™ launch continues this theme of product and market expansion.

Key Terms

metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, randomized controlled trials, double-blind, +4 more

8 terms

metabolic dysfunction-associated steatotic liver disease medical

"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)..."

A common chronic liver condition marked by excess fat in the liver linked to metabolic problems like obesity, diabetes, or high blood pressure; it ranges from harmless fat buildup to inflammation and scarring. Investors care because its high and growing prevalence drives demand for diagnostics, monitoring tools, drugs, and related healthcare services—think of it like a market need created by a widespread health problem that fuels product and treatment opportunities.

non-alcoholic fatty liver disease medical

"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)..."

Non-alcoholic fatty liver disease is a condition where excess fat builds up in the liver of people who drink little or no alcohol; the liver can become inflamed and scarred over time, reducing its ability to function. Investors should care because its large and growing patient population drives demand for diagnostics, treatments, monitoring tools and healthcare services—think of it like a slowly spreading problem in a factory that creates ongoing repair and replacement business opportunities across pharmaceuticals, medical devices, and insurers.

randomized controlled trials medical

"clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials."

Randomized controlled trials are studies where participants are randomly assigned to receive either a new treatment or a comparison (such as a standard treatment or placebo), so outcomes can be fairly compared like flipping a coin to decide teams. For investors, they matter because they provide the most reliable evidence about whether a drug, device or intervention actually works and is safe, which influences regulatory approval, market demand and the financial outlook of companies developing them.

double-blind medical

"validated in two independent randomized, double-blind, placebo-controlled clinical trials."

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"validated in two independent randomized, double-blind, placebo-controlled clinical trials."

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

metabolic syndrome medical

"with the condition closely linked to obesity, type 2 diabetes, and metabolic syndrome."

A cluster of common health problems—usually high blood pressure, high blood sugar, excess belly fat, and abnormal blood fats—that often occur together and raise the risk of heart disease, stroke and diabetes. Think of it like a car dashboard with several warning lights on at once: because the issues reinforce each other, they lead to bigger long-term healthcare needs and spending. Investors care because it drives demand for drugs, devices, diagnostics, chronic-care services and workplace health programs, shaping market size and regulatory attention.

ld50 medical

"Safety Profile | LD50 >5,000 mg/kg | No histopathological toxicity (90-day study)..."

LD50 (lethal dose 50%) is a standard toxicology measure that estimates the amount of a substance, usually given per unit of body weight, expected to kill half of a test population in controlled studies. For investors, LD50 gives a simple way to compare how dangerous a chemical or drug may be, signaling potential safety problems, regulatory hurdles, liability risks, and whether extra testing or protective measures could affect development costs and marketability—think of it as how much of a product would be toxic to half the users.

gmp-certified regulatory

"manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities..."

GMP-certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice rules that ensure products are made consistently, safely, and meet quality standards. Think of it like a professional kitchen that follows strict recipes, cleanliness rules and checks so meals are safe every time. For investors, GMP certification lowers regulatory and product-risk, supports market access and brand trust, and can reduce the chance of costly recalls or production shutdowns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Powered by BergacynFF^®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.

CHICAGO, IL / ACCESS Newswire / April 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. launch of Liv18^™, a next-generation liver health supplement powered by BergacynFF^®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.

The Liver Fat Epidemic: $7+ Billion Projected U.S. Market Opportunity

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as one of the most prevalent and underdiagnosed conditions in the United States. More than 30% of adults are estimated to be affected, with the condition closely linked to obesity, type 2 diabetes, and metabolic syndrome. While recent therapeutic advancements have emerged for certain patient populations, significant unmet need remains for safe, accessible, and preventive solutions supporting liver and metabolic health.

>30% of U.S. adults affected by NAFLD/MASLD

$4.6B U.S. liver health supplements market

4.9% CAGR projected growth through 2035

Sources: Precedence Research

The Science Behind Liv18^™: BergacynFF^®

Liv18™ is built on BergacynFF^®, a patented extract blend of Citrus bergamia (Italian bergamot) and Cynara cardunculus sylvestris (wild Italian artichoke thistle leaf). The ingredient delivers a proprietary profile of bergamot polyphenols (17% flavonone content), bergamot pulp fibers, and artichoke sesquiterpenes (5% cynaropicrin), whose synergistic action has been validated in two independent randomized, double-blind, placebo-controlled clinical trials.

Clinical Evidence Summary:

Study	Population	Key Findings	Publication
Study 1 - 16 weeks	80 subjects, NAFLD + Type 2 Diabetes	ALT ↓15 pts, AST ↓18 pts (p<0.05). Liver fat regressed 2 levels (severe → mild). Reduced TNF-α, oxidative stress, improved vascular function (p<0.001).	J. Traditional & Complementary Medicine, Feb 2020
Study 2 - 12 weeks	102 subjects, non-diabetic, age 35-70, liver steatosis	Liver fat ↓9% vs placebo. In subjects >50 yrs: ↓15% (p<0.05). Weight loss: 9.6 lbs vs 5.2 lbs placebo. Effect attributed solely to BergacynFF®.	Frontiers in Endocrinology, Aug 2020

BergacynFF^® is patented for composition, manufacturing process, and application in the therapeutic support of healthy liver fat levels.

Liv18^™ - Product Profile

Brand Name	Liv18™
Active Ingredient	BergacynFF® 600 mg per serving
Botanical Sources	Citrus bergamia (bergamot) + Cynara cardunculus sylvestris (wild artichoke)
Patent Status	Patented for composition, process & liver fat application
Dosage Form	Capsules
Recommended Use	600 mg/day - 2 capsules (300 mg each) with food, or 1 capsule x2 daily
Clinical Claims	Supports healthy liver fat levels • Promotes weight management • Antioxidant & anti-inflammatory action • Cardioprotective vascular support
Target Consumer	Adults 35+, especially 50+ | Overweight/obese individuals | Metabolic syndrome | NAFLD/MASLD concern | Preventive liver health
Label Claim Basis	2 published RCTs (600 mg/day; DBRPC design)
Safety Profile	LD50 >5,000 mg/kg | No histopathological toxicity (90-day study) | Adverse events ≤ placebo

Why Liv18^™ Stands Apart

• Only liver fat supplement in its category powered by BergacynFF^®, exclusively distributed in the U.S.

• Two independent published RCTs at the exact commercial dose (600 mg/day), not extrapolated from animal or in vitro data

• Clinically demonstrated 9 to 15 percent liver fat reduction vs placebo, with superior effect in adults over 50

• Synergistic botanical blend, outperforms stand-alone bergamot or artichoke extract in head-to-head trial

• Proven weight loss benefit, approximately 2x the weight loss of diet alone over 12 weeks

• Exceptional safety profile, adverse events at or below placebo levels

• No widely accessible, preventive solutions currently exist for addressing liver fat accumulation, creating a substantial opportunity for science-backed nutraceutical approaches.

• Solvent-free, excipient-free, clean-label formulation aligned with premium supplement consumer expectations

U.S. Market Entry and Manufacturing Strategy

Liv18^™ is expected to launch in Q2 2026 across multiple distribution channels in the United States, including e-commerce platforms, health and specialty retail outlets, and healthcare practitioner channels, supported by targeted consumer awareness and outreach initiatives.

All Liv18^™ products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company's commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.

Greg Siokas, CEO of Cosmos Health, stated: "Liv18 represents everything Cosmos stands for: science-backed, clinically validated, and formulated to make a real difference. With BergacynFF^® as its foundation, backed by two published randomized controlled trials, Liv18 brings genuinely differentiated liver health support to the U.S. market at a time when demand has never been higher. This launch represents another important milestone in our continued expansion in the United States, supporting our strategy of introducing differentiated products targeting large and growing health categories."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life^®, Mediterranation^®, bio-bebe^®, C-Sept^® and C-Scrub^®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

FAQ

When will Cosmos Health (COSM) launch Liv18 in the United States?

Cosmos Health plans a U.S. launch of Liv18 in Q2 2026. According to Cosmos Health, the rollout will include e‑commerce, retail, and practitioner channels with targeted consumer outreach.

What clinical evidence supports Liv18 (COSM) and what dose was used?

Liv18 is supported by two randomized, double‑blind, placebo‑controlled trials at 600 mg/day. According to Cosmos Health, studies showed liver fat reductions of 9–15% versus placebo at that dose.

How much liver fat reduction did Liv18 show in clinical trials for COSM?

Clinical trials reported 9% average liver fat reduction versus placebo, up to 15% in subjects over 50. According to Cosmos Health, these results came from two independent published RCTs.

How will Liv18 be manufactured and where, per Cosmos Health (COSM)?

All U.S. Liv18 products will be made in GMP, FDA‑registered, UL‑audited U.S. facilities. According to Cosmos Health, domestic manufacturing reduces tariff exposure and logistical risks.

What is the active ingredient in Liv18 and its patent status for COSM?

Liv18 contains BergacynFF® (600 mg/day), a patented botanical blend of bergamot and wild artichoke. According to Cosmos Health, BergacynFF® is patented for composition, manufacturing, and liver fat application.

What market opportunity does Liv18 target for Cosmos Health (COSM)?

Liv18 targets the U.S. liver health supplements market valued at $4.6B with a projected 4.9% CAGR through 2035. According to Cosmos Health, high MASLD prevalence drives preventive supplement demand.